EMEA-002414-PIP01-18
Key facts
| Active substance |
Humanized anti-CD19, Fc engineered, monoclonal antibody (XmAb5871)
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0274/2019
|
| PIP number |
EMEA-002414-PIP01-18
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of immunoglobulin G4-related disease
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Zenas Biopharma (USA) LLC
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|